| Literature DB >> 36234805 |
Efrén V García-Báez1, Itzia I Padilla-Martínez1, Alejandro Cruz1, Martha C Rosales-Hernández2.
Abstract
Benzimidazole is an important heterocyclic fragment, present in many biologically active compounds with a great variety of therapeutic purposes. Most of the benzimidazole activities are explained through the existence of 1,3-tautomeric equilibrium. As the binding affinity of each tautomer to a protein target depends on an established bioactive conformation, the effect of tautomers on the ligand protein binding mechanism is determinant. In this work, we searched and analyzed a series of reported 13C-NMR spectra of benzazoles and benzazolidine-2-thiones with the purpose of estimating their tautomeric equilibrium. Herein, several approaches to determine this problem are presented, which makes it a good initial introduction to the non-expert reader. This chemical shift difference and C4/C7 signals of benzimidazolidine-2-thione and 1-methyl-2-thiomethylbenzimidazole as references were used in this work to quantitatively calculate, in solution, the pyrrole-pyridine tautomeric ratio in equilibrium. The analysis will help researchers to correctly assign the chemical shifts of benzimidazoles and to calculate their intracyclic or exocyclic tautomeric ratio as well as mesomeric proportion in benzimidazoles.Entities:
Keywords: 13C NMR; benzimidazoles; mesomery; pyridine nitrogen atom; pyrrole nitrogen atom; tautomeric equilibrium
Mesh:
Substances:
Year: 2022 PMID: 36234805 PMCID: PMC9570581 DOI: 10.3390/molecules27196268
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Scheme 1Tautomeric equilibria in organic compounds.
Figure 1(a) Intracyclic and (b) exocyclic tautomerism in benzazoles (BZs).
Effect of heteroatom X on δ-13C in dibenzofused heteroaromatic compounds.
| δ-13C | ||||||
|---|---|---|---|---|---|---|
| Comp. | C1a | C1 | C2 | C3 | C4 | C4a |
| 124.2 | 120.6 | 122.6 | 127.0 | 111.6 | 156.2 | |
| 134.9 | 121.9 | 124.6 | 127.0 | 122.9 | 138.5 | |
| 122.6 | 120.0 | 118.4 | 125.4 | 110.8 | 139.6 | |
13C NMR resonances of 1,3-benzazoles.
| Comp. | C2 | C3a | C4 | C5 | C6 | C7 | C7a | Solv. | Ref. |
|---|---|---|---|---|---|---|---|---|---|
| 152.6 | 140.1 | 120.5 | 125.4 | 124.4 | 110.8 | 150.5 | CDCl3 | [ | |
| 153.8 | 153.2 | 121.8 | 126.1 | 125.4 | 123.6 | 133.6 | CDCl3 | [ | |
| 140.5 | 137.1 | 115.3 | 121.3 | 121.3 | 115.3 | 137.1 | CDCl3 | [ | |
| 141.1 | 137.4 | 114.8 | 122.7 | 122.1 | 114.8 | 137.4 | CD3OD | [ | |
| 141.9 | 138.4 | 115.3 | 121.7 | 121.7 | 115.3 | 138.4 | DMSOd6 | [ | |
| 141.6 | 143.4 | 118.7 | 121.2 | 120.1 | 110.9 | 133.7 | HMPAd18 | [ | |
| 142.6 | 143.0 | 119.9 | 122.1 | 123.0 | 112.2 | 136.1 | Solid | [ | |
| 143.9 | 143.7 | 120.4 | 123.1 | 122.2 | 109.5 | 134.7 | CDCl3 | [ | |
| 144.5 | 143.3 | 119.2 | 122.3 | 121.1 | 110.1 | 134.5 | DMSOd6 | [ |
Figure 2Effect of heteroatom X on C7 and C5 in 1,3-benzoheterazoles 1–3.
Figure 313C chemical shifts as references to calculate the tautomeric proportion of pyrrole–pyridine nitrogen atoms.
Protonation and deprotonation of BMZ 13C in DMSOd6.
| Comp. | C2 | C3a | C4 | C5 | C6 | C7 | C7a |
|---|---|---|---|---|---|---|---|
|
| 142.5 | 139.0 | 116.3 | 122.3 | 122.3 | 116.3 | 139.0 |
|
| 143.6 | 133.8 | 118.3 | 130.0 | 130.0 | 118.3 | 133.8 |
| 153.1 | 146.9 | 116.4 | 116.7 | 116.7 | 116.4 | 146.9 | |
| 153.5 | 147.0 | 116.8 | 117.0 | 117.0 | 116.8 | 147.0 |
Scheme 2Titration process of 2-(aminomethyl)benzimidazole dihydrochloride.
13C NMR resonances of 1-substituted benzimidazoles.
| Comp. | C2 | C3a | C4 | C5 | C6 | C7 | C7a | Solvent | Ref. |
|---|---|---|---|---|---|---|---|---|---|
|
| 143.9 | 143.7 | 120.4 | 123.1 | 122.2 | 109.5 | 134.7 | CDCl3 | [ |
|
| 144.0 | 142.2 | 120.6 | 123.6 | 122.7 | 110.4 | 133.7 | CDCl3 | [ |
|
| 143.9 | 141.4 | 120.6 | 126.0 | 125.1 | 115.5 | 131.4 | CDCl3 | [ |
Effects of 2-subtituted groups on the benzimidazole ring.
| Compound | C2 | C3a | C4 | C5 | C6 | C7 | C7a | Solvent | Ref. |
|---|---|---|---|---|---|---|---|---|---|
| 151.3 | 138.3 | 114.4 | 122.2 | 122.2 | 114.4 | 138.3 | CDCl3 | [ | |
| 157.4 | 139.4 | 114.7 | 122.7 | 122.7 | 114.7 | 139.4 | DMSOd6 | [ | |
| 155.6 | 138.7 | 114.6 | 122.0 | 122.0 | 114.6 | 138.7 | CDCl3 | [ | |
| 142.3 | 135.4 | 118.9 | 120.9 | 121.7 | 110.8 | 134.4 | DMSOd6 | [ | |
| 151.8 | 133.2 | 114.0 | 125.8 | 125.8 | 114.0 | 133.2 | CDCl3 | [ | |
| 151.8 | 144.4 | 119.4 | 123.0 | 122.2 | 111.8 | 135.5 | DMSOd6 | [ | |
| 147.7 | 143.5 | 122.1 | 123.8 | 122.1 | 112.1 | 126.6 | CDCl3 | [ | |
| 147.7 | 143.9 | 122.3 | 126.5 | 123.8 | 112.0 | 133.9 | CDCl3 | [ | |
|
| 144.9 | 136.6 | 116.3 | 124.8 | 124.8 | 116.3 | 136.6 | DMSOd6 |
13C chemical shifts of benzoheterazolidine-2-thiones 10–13 and 2-S-Methyl-benzazoles 14–17.
| Comp. | C2 | C4 | C5 | C6 | C7 | C7a | C3a | Solv. | Ref. | % Npr |
|---|---|---|---|---|---|---|---|---|---|---|
|
| 180.8 | 110.2 | 124.5 | 125.4 | 110.5 | 148.8 | 130.3 | CDCl3 | [ | 93.7 |
|
| 189.7 | 112.3 | 124.0 | 127.0 | 121.6 | 141.2 | 129.3 | DMSOd6 | 77.0 | |
|
| 167.9 | 109.6 | 122.3 | 122.3 | 109.6 | 132.7 | 132.7 | DMSOd6 | 100 | |
|
| 168.3 | 118.3 | 123.4 | 123.4 | 110.1 | 132.6 | 130.8 | DMSOd6 | 8.4 | |
|
| 165.7 | 118.3 | 123.7 | 124.2 | 109.8 | 151.9 | 141.9 | CDCl3 | [ | 8.4 |
|
| 170.7 | 122.0 | 125.4 | 127.4 | 123.3 | 136.1 | 154.4 | CD3OD | [ | 0.0 |
|
| 151.9 | 113.7 | 121.7 | 121.7 | 113.7 | 139.5 | 139.5 | CDCl3 | [ | 56.8 |
|
| 153.2 | 118.0 | 121.8 | 121.8 | 108.3 | 136.8 | 143.3 | CDCl3 | [ | 11.6 |
Alkylbenzimidazolidine-2-selenones 18 and 19 and their diselenide derivatives 20 and 21.
| Comp. | C2 | C3a | C4 | C5 | C6 | C7 | C7a | Solvent | Ref. | N4pr% |
|---|---|---|---|---|---|---|---|---|---|---|
|
| 162.8 | 132.1 | 110.0 | 123.3 | 122.6 | 110.0 | 133.7 | DMSOd6 | [ | 95.8 |
|
| 160.3 | 133.0 | 114.4 | 121.1 | 122.8 | 109.9 | 133.8 | DMSOd6 | [ | 50.5 |
|
| 142.6 | 144.3 | 110.5 | 123.0 | 124.4 | 120.4 | 137.3 | CD2Cl2 | [ | 90.5 |
|
| 145.6 | 145.3 | 114.1 | 121.8 | 121.9 | 118.8 | 136.8 | CD2Cl2 | [ | 52.7 |
Figure 4X and NH shielding electronic effect on the 1,3-benzazolidine-2-thione aromatic ring.
N1-acylbenzoheterazolidine-2-thiones 22.
| Comp. | C2 | C3a | C4 | C5 | C6 | C7 | C7a | Solvent | Npr% | Ref. |
|---|---|---|---|---|---|---|---|---|---|---|
|
| 178.8 | 129.5 | 115.8 | 125.5 | 126.0 | 109.7 | 145.9 | DMSOd6 | 34.7 | [ |
|
| 168.9 | 129.8 | 114.3 | 122.3 | 124.3 | 108.5 | 130.1 | DMSOd6 | 50.5 | [ |
|
| 169.4 | 130.9 | 115.0 | 123.3 | 125.2 | 109.4 | 131.0 | DMSOd6 | 43.1 | [ |
|
| 168.1 | 129.5 | 113.2 | 125.1 | 125.1 | 113.2 | 129.5 | CDCl3 | 62.1 | [ |
Tautomers of omeprazole in THF.
| Claramunt et al. | C2 | C3a | C4 | C5 | C6 | C7 | C7a | Solvent | Npr% |
|---|---|---|---|---|---|---|---|---|---|
|
| 155.4 | 146.0 | 101.1 | 157.4 | 115.3 | 113.1 | 129.9 | THF-d8 | 63 |
|
| 153.5 | 140.2 | 121.6 | 114.2 | 158.2 | 94.0 | 136.5 | THF-d8 | 37 |